AGM/EGMApr 30, 2026, 08:21 AM
Valion Bio to Vote on Equity Plan, Multiple Share Issuances
AI Summary
Valion Bio, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on May 28, 2026. Stockholders will vote on several key proposals, including the election of a Class II director and an amendment to the 2021 Equity Incentive Plan to increase authorized shares by 2,581,608. Additionally, the company seeks approval for multiple common stock issuances related to convertible preferred stock, warrants, and an equity line of credit, all in accordance with Nasdaq Listing Rule 5635(d).
Key Highlights
- Annual Meeting of Stockholders to be held virtually on May 28, 2026, at 10:00 a.m. Pacific Time.
- Proposes to elect one Class II director to hold office until the 2029 annual meeting.
- Seeks approval to increase shares authorized for the 2021 Equity Incentive Plan by 2,581,608 shares.
- Requests ratification of Rosenberg Rich Baker Berman, P.A. as independent auditor for fiscal year 2026.
- Proposes approval for common stock issuance upon conversion of Series C Preferred Stock and warrants from Dec 9, 2025 agreement.
- Seeks approval for common stock issuance upon conversion of Senior Secured Convertible Note and warrant to 3i, LP from Dec 9, 2025 agreement.
- Proposes approval for common stock issuance upon conversion of Series B Preferred Stock and warrants to 3i from April 29, 2025 agreement.
- Requests approval for common stock issuance to Tumim Stone Capital, LLC via an Equity Line of Credit from Feb 6, 2026 agreement.
Price Impact
More from TIVC